Barclays
IMRX icon

Barclays’s Immuneering IMRX Stock Holding History

Barclays’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$643K Sell
121,978
-108,748
-47% -$557K ﹤0.01% 3036
2025
Q4 		$1.52M Buy
230,726
+208,608
+943% +$1.34M ﹤0.01% 3128
2025
Q3 		$155K Buy
22,118
+12,194
+123% +$63.3K ﹤0.01% 4443
2025
Q2 		$33.4K Hold
9,924
– – ﹤0.01% 4765
2025
Q1 		$15.1K Hold
9,924
– – ﹤0.01% 4823
2024
Q4 		$21.8K Hold
9,924
– – ﹤0.01% 4912
2024
Q3 		$24.7K Sell
9,924
-251
-2% -$365 ﹤0.01% 4872
2024
Q2 		$13K Sell
10,175
-15,618
-61% -$25.7K ﹤0.01% 4495
2024
Q1 		$74.5K Sell
25,793
-9,130
-26% -$51.2K ﹤0.01% 4528
2023
Q4 		$257K Buy
34,923
+26,744
+327% +$178K ﹤0.01% 4309
2023
Q3 		$62.8K Buy
8,179
+35
+0.4% +$322 ﹤0.01% 3772
2023
Q2 		$82.6K Buy
8,144
+2,927
+56% +$28.1K ﹤0.01% 3631
2023
Q1 		$50.7K Sell
5,217
-1,541
-23% -$8.75K ﹤0.01% 4441
2022
Q4 		$32.8K Buy
6,758
+2,168
+47% +$19.2K ﹤0.01% 4694
2022
Q3 		$65K Buy
4,590
+430
+10% +$3.41K ﹤0.01% 3697
2022
Q2 		$22K Sell
4,160
-3,068
-42% -$16.4K ﹤0.01% 4357
2022
Q1 		$47K Buy
+7,228
New +$69.4K ﹤0.01% 4139

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays's IMRX Position: Q1 2026 in Review

Barclays reduced its Immuneering (IMRX) stake by 47% in Q1 2026, selling an estimated $557K and leaving 121,978 shares worth $643K. The position accounts for ﹤0.01% of the portfolio, ranked #3036.

Barclays first reported a position in IMRX in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.52M in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Barclays held 121,978 shares of Immuneering worth $643K as of Q1 2026.
  • Barclays sold 108,748 Immuneering shares in Q1 2026, an estimated $557K.
  • Immuneering made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3036 holding.
  • Barclays first reported a position in Immuneering in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Immuneering position peaked at $1.52M in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.